Axesor Rating raises Pharma Mar's rating from "BB-" with Positive outlook to "BB+" with Stable outlook. The biotechnology group is focused on the development of anti-tumour drugs. The company has presence international in the main oncology markets. Its pharmaceutical portfolio includes three drugs under commercialisation, which was reinforced in 2020 with the accelerated approval of Zepzelca. Turnover and EBITDA reached € 270MM and € 163.5MM respectively in 2020, maintaining the net financial debt in negative values. The company has a market capitalisation over € 1.8Bn.